Suppurative thrombophlebitis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 58: Line 58:
|}
|}
|}
|}
===Septic pelvic vein thrombophlebitis===
* Based on the [[CT]] and [[MRI]] findings [[septic pelvic vein thrombophlebitis]] is classified into following categories for management.<ref>{{Cite journal
| author = [[Javier Garcia]], [[Ramzi Aboujaoude]], [[Joseph Apuzzio]] & [[Jesus R. Alvarez]]
| title = Septic pelvic thrombophlebitis: diagnosis and management
| journal = [[Infectious diseases in obstetrics and gynecology]]
| volume = 2006
| pages = 15614
| year = 2006
| month =
| doi = 10.1155/IDOG/2006/15614
| pmid = 17485796
}}</ref>.
:* 1. '''Right ovarian vein thrombosis'''
::* Preferred regimen (1): [[Ertapenem]] 1 g PO qd for 7 days {{and}} [[Enoxaparin]] (1 mg/Kg) initially {{and}}  3–6 months of [[Warfarin]] (INR 2.5)
::* Preferred regimen (2): [[Gentamicin]] 4 mg/kg {{and}} [[Ampicillin]] 2 g  {{and}} [[Clindamycin]] 1200 mg for 7 days {{and}} [[Enoxaparin]] (1 mg/Kg) initially {{and}}  3–6 months [[Warfarin]] (INR 2.5).
::* Note: Repeat [[CT]] scan after 3 months. If negative, stop [[anticoagulation]]. If still positive for [[thrombi]], [[anticoagulate]] for 3 additional months.
:* 2. '''Pelvic branch vein thrombosis'''
::* Preferred regimen (1): [[Ertapenem]]  1 g PO qd for 7 days {{and}} [[Enoxaparin]] (1 mg/Kg) PO for 2 weeks
::* Preferred regimen (2): [[Gentamicin]] (4 mg/kg) PO {{and}} [[Ampicillin]] 2 g PO {{and}} [[Clindamycin]] 1200 mg PO for 7 days {{and}} [[Enoxaparin]] (1 mg/Kg) for 2 weeks.
:* 3. '''Negative for pelvic thrombi'''
::* Preferred regimen (1): [[Ertapenem]] 1 g PO qd for 7 days {{and}} [[Enoxaparin]] (1 mg/Kg) for 1 week
::* Preferred regimen (2): [[Gentamicin]]  (4 mg/kg) PO qd {{and}} [[Ampicillin]] 2 g PO qd {{and}} [[Clindamycin]] 1200 mg PO qd for 7 days {{and}} [[Enoxaparin]] (1 mg/Kg) PO qd for 1 weeks


==References==
==References==
Line 74: Line 98:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Primary care]]
[[Category:Primary care]]
[[Category: Infectious Disease Project]]

Revision as of 20:35, 12 August 2015

Suppurative thrombophlebitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Suppurative thrombophlebitis from other Diseases

Risk Factors

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Case Studies

Case #1

Suppurative thrombophlebitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Suppurative thrombophlebitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Suppurative thrombophlebitis medical therapy

CDC on Suppurative thrombophlebitis medical therapy

Suppurative thrombophlebitis medical therapy in the news

Blogs on Suppurative thrombophlebitis medical therapy

Directions to Hospitals Treating Suppurative thrombophlebitis

Risk calculators and risk factors for Suppurative thrombophlebitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Overview

Medical therapy of Suppurative thrombophlebitis aims to eliminate the source of infection, followed by antibiotic coverage for the detected pathogen. Surgical intervention, anticoagulation is considered after evaluation of the case. Empirical therapy is administered until the blood culture results detect the targeted pathogen.

The role of anticoagulation is uncertain, and should not be routinely used, as there are no controlled studies to determine its role. It is tried when extension of the thrombus is evident even with proper antibiotic use.

Peripheral Vein Suppurative Thrombophlebitis

Till the blood culture results detect the targeted pathogen, empiric antibiotic therapy is given aiming to include an agent with activity against staphylococci plus an agent with activity against enterobacteriaceae.

Peripheral Vein Suppurative Thrombophlebitis
Vancomycin 15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose x minimum of 2Wks
PLUS
Ceftriaxone 1 g IV daily x minimum of 2Wks

Jugular Vein Suppurative Thrombophlebitis

A beta-lactamase resistant beta-lactam antibiotic should be used in cases of jugular vein suppurative thrombophlebitis.

Jugular Vein Suppurative Thrombophlebitis
Ampicillin-sulbactam 3 g every six hours x 4 Wks
OR
Piperacillin-tazobactam 4.5 g every six hours x 4 Wks
OR
Ticarcillin-clavulanate 3.1 g every six hours x 4 Wks
PLUS
Vancomycin 15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose x 4 Wks

Vena Cava Suppurative Thrombophlebitis

Vena Cava Suppurative Thrombophlebitis
Vancomycin 15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose x 4 to 6 Wks
PLUS
Ceftriaxone 1 g IV daily x 4 to 6 Wks

Septic pelvic vein thrombophlebitis

  • 1. Right ovarian vein thrombosis
  • 2. Pelvic branch vein thrombosis
  • 3. Negative for pelvic thrombi

References

  1. Javier Garcia, Ramzi Aboujaoude, Joseph Apuzzio & Jesus R. Alvarez (2006). "Septic pelvic thrombophlebitis: diagnosis and management". Infectious diseases in obstetrics and gynecology. 2006: 15614. doi:10.1155/IDOG/2006/15614. PMID 17485796.


Template:WikiDoc Sources